Mizuki Nishino, MD, MPH

Mizuki Nishino, MD, MPH

Contact Information

Office Phone Number

617-632-2595

Fax

617-582-8574

Researcher

Physician

Physician
Vice Chair of Faculty Development, Department of Imaging
Professor of Radiology, Harvard Medical School

Centers/Programs

Clinical Interests

Immunotherapy, Lung cancer, Oncologic imaging, Precision oncology, Thoracic imaging

Board Certification

  • Diagnostic Radiology, 2008

Fellowship

  • Beth Israel Deaconess Medical Center, Thoracic Imaging

Residency

  • Beth Israel Deaconess Medical Center, Diagnostic Radiology

Medical School

  • Kyoto University Faculty of Medicine, Japan

Recent Awards

  • R01 award from the National Cancer Institute (PI: Nishino, 1R01CA203636, 2017-2021) “Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment”

    2017

  • Magna Cum Laude- Dynamic Chest Radiography Using Flat Panel Detector System: Technique and Application. RSNA 2016, Chicago, IL, Nov

    2016

  • Cum Laude- Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. RSNA 2016, Chicago, IL, Nov

    2016

  • Merck Investigator Studies Program (PI: Nishino, 2016-2018). “Quantitative imaging analysis during pembrolizumab therapy in advanced melanoma patients: providing an objective marker for survival and therapeutic decisions”

    2016

  • Editors' Recognition Award for Distinction in Reviewing, Journal of Thoracic Imaging.

    2014, 2015

  • Diagnosis Please Award for Cases 205-216 published in 2014. Announcement in: Radiology. 2015; 277: 314-7.

    2014

  • Diagnosis Please Award for Cases 181-192 published in 2012. Announcement in: Radiology. 2013; 269: 627-31.

    2012

  • Dana-Farber Cancer Institute Fellowship for the Eleanor and Miles Shore 50th Anniversary Fellowship Program. (PI: Nishino, 2012) “Quantification of Apoptotic Activity in Non-small-cell Lung Cancer treated with Targeted Therapy: A pilot study.”

    2012

  • K 23 Award from the National Cancer Institute (5K23CA157631, PI: Nishino, 2011-2016) “CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation”

    2011

  • RSNA Research Scholar Grant, RSNA R&E Foundation (PI: Nishino, 2009-2011) "Chronological Analysis of Tumor Size, Volume and CT attenuation coefficient in Women with Adenocarcinoma of the Lung Treated with Erlotinib"

    2009

Publications

    • Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. Eur Radiol. 2023 Oct; 33(10):7284-7293. View in: Pubmed

    • Interstitial lung abnormalities are associated with decreased mean telomere length. Eur Respir J. 2022 08; 60(2). View in: Pubmed

    • Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022 08 01; 8(8):1160-1168. View in: Pubmed

    • Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040. View in: Pubmed

    • The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. Thorax. 2023 06; 78(6):559-565. View in: Pubmed

    • Blood gene expression risk profiles and interstitial lung abnormalities: COPDGene and ECLIPSE cohort studies. Respir Res. 2022 Jun 17; 23(1):157. View in: Pubmed

    • Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality: The COPDGene Study. Radiology. 2022 09; 304(3):694-701. View in: Pubmed

    • Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2022 06; 17(6):779-792. View in: Pubmed

    • Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022 May; 106:102378. View in: Pubmed

    • Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma. Radiology. 2022 06; 303(3):673-674. View in: Pubmed

    • Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. Chest. 2022 04; 161(4):999-1010. View in: Pubmed

    • Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 03; 17(3):399-410. View in: Pubmed

    • Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer. 2021 11; 9(11). View in: Pubmed

    • Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021 11; 5:1603-1610. View in: Pubmed

    • Diagnosis Please Certificates of Recognition Awarded to Four Individuals and to International and North American Radiology Resident Groups. Radiology. 2021 12; 301(3):497-501. View in: Pubmed

    • Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. J Thorac Oncol. 2022 01; 17(1):154-159. View in: Pubmed

    • Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. J Thorac Imaging. 2023 Mar 01; 38(2):82-87. View in: Pubmed

    • SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187. View in: Pubmed

    • The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality. Am J Respir Crit Care Med. 2021 05 01; 203(9):1149-1157. View in: Pubmed

    • Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 5. View in: Pubmed

    • Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study. Eur J Radiol Open. 2021; 8:100334. View in: Pubmed

    • Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021 03; 9(3). View in: Pubmed

    • Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. AJR Am J Roentgenol. 2022 01; 218(1):19-27. View in: Pubmed

    • Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study. Cancer Imaging. 2021 Jan 19; 21(1):14. View in: Pubmed

    • Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021 03; 159(3):1107-1125. View in: Pubmed

    • Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology. 2021 03; 298(3):550-566. View in: Pubmed

    • Management of Pulmonary Nodules in Oncologic Patients: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021 06; 216(6):1423-1431. View in: Pubmed

    • The associations of interstitial lung abnormalities with cancer diagnoses and mortality. Eur Respir J. 2020 12; 56(6). View in: Pubmed

    • Dynamic Chest X-Ray Using a Flat-Panel Detector System: Technique and Applications. Korean J Radiol. 2021 04; 22(4):634-651. View in: Pubmed

    • Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. J Rheumatol. 2021 05; 48(5):656-663. View in: Pubmed

    • Diagnosis Please Certificates of Recognition Awarded to Five Individuals and to International and North American Radiology Resident Groups. Radiology. 2020 Nov; 297(2):247-250. View in: Pubmed

    • CT Volumetry for Lung-RADS Classification of Solid Nodules. Radiology. 2020 12; 297(3):685-686. View in: Pubmed

    • Projected lung areas using dynamic X-ray (DXR). Eur J Radiol Open. 2020; 7:100263. View in: Pubmed

    • Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020 Nov; 132:109275. View in: Pubmed

    • Radiomics to Predict Invasiveness of Part-Solid Adenocarcinoma of the Lung. Radiology. 2020 11; 297(2):459-461. View in: Pubmed

    • A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144. View in: Pubmed

    • Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology. 2020 10; 297(1):87-96. View in: Pubmed

    • Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2). View in: Pubmed

    • Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. J Immunother Cancer. 2020 06; 8(1). View in: Pubmed

    • Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality. Eur J Radiol. 2020 Aug; 129:109073. View in: Pubmed

    • Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. Lung Cancer. 2020 07; 145:132-139. View in: Pubmed

    • Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814. View in: Pubmed

    • Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142. View in: Pubmed

    • Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):e435-e444. View in: Pubmed

    • Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107. View in: Pubmed

    • Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625. View in: Pubmed

    • Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210. View in: Pubmed

    • Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411. View in: Pubmed

    • Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 12 01; 200(11):1402-1413. View in: Pubmed

    • Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. View in: Pubmed

    • Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Oct 01; 5(10):1421-1429. View in: Pubmed

    • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659. View in: Pubmed

    • Diagnosis Please Certificates of Recognition Awarded to Three Individuals and to International and North American Radiology Resident Groups. Radiology. 2019 11; 293(2):241-244. View in: Pubmed

    • Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2019 09 15; 200(6):e31-e43. View in: Pubmed

    • Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology. 2019 10; 293(1):15-29. View in: Pubmed

    • Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis Rheumatol. 2019 09; 71(9):1472-1482. View in: Pubmed

    • Using CT to Evaluate Visceral Pleural Invasion: Caution Is Advised. Radiology. 2019 Sep; 292(3):750-751. View in: Pubmed

    • Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. Am J Respir Crit Care Med. 2019 07 15; 200(2):175-183. View in: Pubmed

    • Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934. View in: Pubmed

    • Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY). 2019 05; 44(5):1917-1927. View in: Pubmed

    • Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112. View in: Pubmed

    • The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. Lung Cancer. 2019 06; 132:79-86. View in: Pubmed

    • Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2019 04; 16(4):447-454. View in: Pubmed

    • Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131. View in: Pubmed

    • Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. View in: Pubmed

    • Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements Using Radiomics. J Thorac Imaging. 2019 Mar; 34(2):103-115. View in: Pubmed

    • Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. Eur J Radiol. 2019 Apr; 113:59-65. View in: Pubmed

    • M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754. View in: Pubmed

    • Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. Hum Pathol. 2019 04; 86:93-101. View in: Pubmed

    • Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. Eur J Radiol. 2019 Mar; 112:28-36. View in: Pubmed

    • Perinodular Radiomic Features to Assess Nodule Microenvironment: Does It Help to Distinguish Malignant versus Benign Lung Nodules? Radiology. 2019 Mar; 290(3):793-795. View in: Pubmed

    • Imaging of Histiocytosis in the Era of Genomic Medicine. Radiographics. 2019 Jan-Feb; 39(1):95-114. View in: Pubmed

    • Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology. 2019 01; 290(1):9-22. View in: Pubmed

    • Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer. 2019 01; 127:168. View in: Pubmed

    • Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76. View in: Pubmed

    • PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 10 01; 29(10):2085-2091. View in: Pubmed

    • Diagnosis Please Certificates of Recognition Awarded to Three Individuals and to International and North American Radiology Resident Groups. Radiology. 2018 11; 289(2):277-279. View in: Pubmed

    • Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5963-5976. View in: Pubmed

    • Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer. 2018 09; 123:60-69. View in: Pubmed

    • Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:1019-1029. View in: Pubmed

    • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835. View in: Pubmed

    • An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. J Thorac Oncol. 2018 08; 13(8):e131-e133. View in: Pubmed

    • Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunol Res. 2018 06; 6(6):630-635. View in: Pubmed

    • Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. Am J Respir Crit Care Med. 2018 04 01; 197(7):955-958. View in: Pubmed

    • Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858. View in: Pubmed

    • Radiological features and metastatic patterns of thymic neuroendocrine tumours. Clin Radiol. 2018 05; 73(5):479-484. View in: Pubmed

    • The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur Respir J. 2017 09; 50(3). View in: Pubmed

    • Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics. 2017 Sep-Oct; 37(5):1371-1387. View in: Pubmed

    • Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin Cancer Res. 2017 Nov 01; 23(21):6661-6672. View in: Pubmed

    • Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744. View in: Pubmed

    • Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017 Nov; 14(11):655-668. View in: Pubmed

    • Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. View in: Pubmed

    • Risk of Bias and Heterogeneity-Reply. JAMA Oncol. 2017 06 01; 3(6):858-859. View in: Pubmed

    • Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2017; 1. View in: Pubmed

    • Osimertinib in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 05 18; 376(20):1992-3. View in: Pubmed

    • Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features. Occup Environ Med. 2017 10; 74(10):756-761. View in: Pubmed

    • Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma. JAMA Oncol. 2017 05 01; 3(5):703-704. View in: Pubmed

    • Difference in the craniocaudal gradient of the maximum pixel value change rate between chronic obstructive pulmonary disease patients and normal subjects using sub-mGy dynamic chest radiography with a flat panel detector system. Eur J Radiol. 2017 Jul; 92:37-44. View in: Pubmed

    • Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns. J Clin Oncol. 2017 05 10; 35(14):1628-1629. View in: Pubmed

    • Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol. 2017 Jan-Feb; 18(1):42-53. View in: Pubmed

    • Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017 01 01; 195(1):138-141. View in: Pubmed

    • Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. Eur J Radiol. 2017 Mar; 88:15-20. View in: Pubmed

    • Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4:84. View in: Pubmed

    • Difference in diaphragmatic motion during tidal breathing in a standing position between COPD patients and normal subjects: Time-resolved quantitative evaluation using dynamic chest radiography with flat panel detector system ("dynamic X-ray phrenicography"). Eur J Radiol. 2017 Feb; 87:76-82. View in: Pubmed

    • Time-Resolved Quantitative Analysis of the Diaphragms During Tidal Breathing in a Standing Position Using Dynamic Chest Radiography with a Flat Panel Detector System ("Dynamic X-Ray Phrenicography"): Initial Experience in 172 Volunteers. Acad Radiol. 2017 04; 24(4):393-400. View in: Pubmed

    • Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016 12 15; 194(12):1514-1522. View in: Pubmed

    • Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 01; 2(12):1607-1616. View in: Pubmed

    • Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View in: Pubmed

    • PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. Br J Haematol. 2018 03; 180(5):752-755. View in: Pubmed

    • PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060. View in: Pubmed

    • Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Nov 15; 122(22):3456-3463. View in: Pubmed

    • Pseudoprogression and Measurement Variability. J Clin Oncol. 2016 10 01; 34(28):3480-1. View in: Pubmed

    • Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res. 2017 Jan 01; 23(1):204-213. View in: Pubmed

    • Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. Am J Respir Crit Care Med. 2016 07 01; 194(1):77-83. View in: Pubmed

    • Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. J Immunother Cancer. 2016; 4:30. View in: Pubmed

    • Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes. Clin Radiol. 2016 Oct; 71(10):1010-1017. View in: Pubmed

    • Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality. Eur J Radiol Open. 2016; 3:86-94. View in: Pubmed

    • Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterization-iLEAD study. Eur J Radiol Open. 2016; 3:67-73. View in: Pubmed

    • Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA. 2016 Feb 16; 315(7):672-81. View in: Pubmed

    • Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2016 Apr; 4(4):289-93. View in: Pubmed

    • Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016 Jan; 14(1):105-13. View in: Pubmed

    • Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36. View in: Pubmed

    • Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016 Jan; 53:163-70. View in: Pubmed

    • Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol. 2015 Nov; 10(11):1648-52. View in: Pubmed

    • Pulmonary cysts identified on chest CT: are they part of aging change or of clinical significance? Thorax. 2015 Dec; 70(12):1156-62. View in: Pubmed

    • A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulm Med. 2015 Oct 29; 15:134. View in: Pubmed

    • Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist. 2015 Sep; 20(9):1077-83. View in: Pubmed

    • Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015 Jul 16; 373(3):288-90. View in: Pubmed

    • Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92. View in: Pubmed

    • Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med. 2015 Jun 15; 191(12):1403-12. View in: Pubmed

    • Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. Radiology. 2015 Dec; 277(3):733-40. View in: Pubmed

    • Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. J Thorac Oncol. 2015 Jun; 10(6):951-9. View in: Pubmed

    • Hormonal therapy in oncology: a primer for the radiologist. AJR Am J Roentgenol. 2015 Jun; 204(6):W620-30. View in: Pubmed

    • Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. Eur Radiol. 2016 Jan; 26(1):286-95. View in: Pubmed

    • Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91. View in: Pubmed

    • Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. Eur Radiol. 2016 Jan; 26(1):15-24. View in: Pubmed

    • Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7. View in: Pubmed

    • Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015 Jul; 84(7):1259-68. View in: Pubmed

    • Paraseptal emphysema: Prevalence and distribution on CT and association with interstitial lung abnormalities. Eur J Radiol. 2015 Jul; 84(7):1413-8. View in: Pubmed

    • RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol. 2015 Mar; 204(3):W282-8. View in: Pubmed

    • Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. Radiographics. 2015 Mar-Apr; 35(2):455-74. View in: Pubmed

    • Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004. View in: Pubmed

    • Reply to "Usefulness of CT in differentiating lymphoid thymic hyperplasia from true thymic hyperplasia: added value of thymic measurements and CT attenuation". AJR Am J Roentgenol. 2015 Jan; 204(1):W115. View in: Pubmed

    • Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015 Jan; 67(1):28-38. View in: Pubmed

    • Anterior Mediastinal Masses in the Framingham Heart Study: Prevalence and CT Image Characteristics. Eur J Radiol Open. 2015; 2:26-31. View in: Pubmed

    • Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; 2(1):40. View in: Pubmed

    • Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014 Nov-Dec; 34(7):1908-28. View in: Pubmed

    • Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov; 86(2):241-6. View in: Pubmed

    • Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014 Jul; 146(1):41-50. View in: Pubmed

    • Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2:17. View in: Pubmed

    • Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities. Acad Radiol. 2014 Jun; 21(6):733-42. View in: Pubmed

    • Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol. 2014 Aug; 69(8):841-8. View in: Pubmed

    • Intrathymic cyst: clinical and radiological features in surgically resected cases. Clin Radiol. 2014 Jul; 69(7):732-8. View in: Pubmed

    • 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014 May; 19(5):507-14. View in: Pubmed

    • State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014 Apr; 271(1):6-27. View in: Pubmed

    • Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol. 2014 Mar; 202(3):471-8. View in: Pubmed

    • Clinical problem solving: utility of sonography in oncologic patients. J Ultrasound Med. 2014 Jan; 33(1):9-22. View in: Pubmed

    • Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014 Mar 01; 120(5):711-21. View in: Pubmed

    • Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol. 2013 Oct; 201(4):811-24. View in: Pubmed

    • Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8. View in: Pubmed

    • Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68. View in: Pubmed

    • Intrathoracic malignant peripheral nerve sheath tumors: imaging features and implications for management. Radiol Oncol. 2013; 47(3):230-8. View in: Pubmed

    • Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15; 19(16):4532-40. View in: Pubmed

    • RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013 Jul; 201(1):W64-71. View in: Pubmed

    • Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936-43. View in: Pubmed

    • MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013 Jun 06; 368(23):2192-200. View in: Pubmed

    • Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol. 2013 Mar; 200(3):484-92. View in: Pubmed

    • A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol. 2014 Jan; 83(1):6-19. View in: Pubmed

    • Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84. View in: Pubmed

    • Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8. View in: Pubmed

    • Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov; 78(2):161-6. View in: Pubmed

    • Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012 Jun 29; 12:225-35. View in: Pubmed

    • Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012 Apr; 198(4):737-45. View in: Pubmed

    • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18; 483(7391):613-7. View in: Pubmed

    • Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med. 2012 Apr 01; 185(7):756-62. View in: Pubmed

    • Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med. 2012 Mar 01; 185(5):547-56. View in: Pubmed

    • Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011 Mar 10; 364(10):897-906. View in: Pubmed

    • Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15; 117(16):3860-6. View in: Pubmed

    • Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36. View in: Pubmed

    • CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62. View in: Pubmed

    • Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med. 2010 Oct; 29(10):1499-502. View in: Pubmed

    • New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8. View in: Pubmed

    • Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010 Aug; 195(2):281-9. View in: Pubmed

    • Case 155: Lane-Hamilton syndrome. Radiology. 2010 Mar; 254(3):985-8. View in: Pubmed

    • Volumetric expiratory HRCT of the lung: clinical applications. Thorac Surg Clin. 2010 Feb; 20(1):121-7, viii-ix. View in: Pubmed

    • Volumetric expiratory HRCT of the lung: clinical applications. Radiol Clin North Am. 2010 Jan; 48(1):177-83. View in: Pubmed

    • The spectrum of pulmonary sarcoidosis: variations of high-resolution CT findings and clues for specific diagnosis. Eur J Radiol. 2010 Jan; 73(1):66-73. View in: Pubmed

    • Cine MR imaging of uterine peristalsis in patients with endometriosis. Eur Radiol. 2007 Jul; 17(7):1813-9. View in: Pubmed

    • 3-dimensional adaptive raw-data filter: evaluation in low dose chest multidetector-row computed tomography. J Comput Assist Tomogr. 2006 Nov-Dec; 30(6):933-8. View in: Pubmed

    • Fetal lung volume measurements: determination with MR imaging--effect of various factors. Radiology. 2006 Jul; 240(1):187-93. View in: Pubmed

    • Excessive collapsibility of bronchi in bronchiectasis: evaluation on volumetric expiratory high-resolution CT. J Comput Assist Tomogr. 2006 May-Jun; 30(3):474-8. View in: Pubmed

    • Loss of anteroposterior intralobar attenuation gradient of the lung: Correlation with pulmonary function. Acad Radiol. 2006 May; 13(5):589-97. View in: Pubmed

    • Incidence of pulmonary embolism in younger versus older patients using CT. J Thorac Imaging. 2006 May; 21(2):167-71. View in: Pubmed

    • Coronal reformations of the chest on 64-row multi-detector row CT: evaluation of image quality in comparison with 16-, 8- and 4-row multi-detector row CT. Eur J Radiol. 2006 Aug; 59(2):231-7. View in: Pubmed

    • The thymus: a comprehensive review. Radiographics. 2006 Mar-Apr; 26(2):335-48. View in: Pubmed

    • Evaluation of pulmonary embolisms using coronal reformations on 64-row multidetector-row computed tomography: Comparison with axial images. J Comput Assist Tomogr. 2006 Mar-Apr; 30(2):233-7. View in: Pubmed

    • Evaluation of thoracic abnormalities on 64-row multi-detector row CT: comparison between axial images versus coronal reformations. Eur J Radiol. 2006 Jul; 59(1):33-41. View in: Pubmed

    • Benign or malignant?: differentiating breast lesions with computed tomography attenuation values on dynamic computed tomography mammography. J Comput Assist Tomogr. 2005 Nov-Dec; 29(6):772-9. View in: Pubmed

    • Volumetric expiratory HRCT imaging with MSCT. J Thorac Imaging. 2005 Aug; 20(3):176-85. View in: Pubmed

    • Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol. 2005 Jun; 12(6):722-7. View in: Pubmed

    • Bronchomalacia in sarcoidosis: evaluation on volumetric expiratory high-resolution CT of the lung. Acad Radiol. 2005 May; 12(5):596-601. View in: Pubmed

    • Comparison of artifacts on coronal reformation and axial CT pulmonary angiography images using single-detector and 4- and 8-detector multidetector-row helical CT scanners. Acad Radiol. 2005 May; 12(5):602-7. View in: Pubmed

    • Tracheobronchomalacia: comparison between end-expiratory and dynamic expiratory CT for evaluation of central airway collapse. Radiology. 2005 May; 235(2):635-41. View in: Pubmed

    • A simple method for displaying cine images on web-based teaching files. AJR Am J Roentgenol. 2005 Feb; 184(2):691-4. View in: Pubmed

    • Functional evaluation of the postoperative gastrointestinal tract using kinematic MR imaging: Quantitative assessment of peristaltic activity. Eur J Radiol. 2005 Feb; 53(2):263-7. View in: Pubmed

    • Uterine contractions evaluated on cine MR imaging in patients with uterine leiomyomas. Eur J Radiol. 2005 Jan; 53(1):142-6. View in: Pubmed

    • Volumetric expiratory high-resolution CT of the lung. Eur J Radiol. 2004 Nov; 52(2):180-4. View in: Pubmed

    • Sagittal reformations of volumetric inspiratory and expiratory high-resolution CT of the lung. Acad Radiol. 2004 Nov; 11(11):1282-90. View in: Pubmed

    • Architecture of the lung: morphology and function. J Thorac Imaging. 2004 Oct; 19(4):221-7. View in: Pubmed

    • Comprehensive innovative solution for resident education using the Intranet Journal of Chest Radiology. Acad Radiol. 2004 Oct; 11(10):1149-52. View in: Pubmed

    • Use of personal digital assistants in diagnostic radiology resident education. Acad Radiol. 2004 Oct; 11(10):1153-8. View in: Pubmed

    • MR imaging of ovarian hemorrhage. Eur J Radiol. 2004 Jul; 51(1):34-40. View in: Pubmed

    • A mobile solution: PDA-based platform for radiology information management. AJR Am J Roentgenol. 2004 Jul; 183(1):237-42. View in: Pubmed

    • Coronal reformations of volumetric expiratory high-resolution CT of the lung. AJR Am J Roentgenol. 2004 Apr; 182(4):979-82. View in: Pubmed

    • Value of volumetric data acquisition in expiratory high-resolution computed tomography of the lung. J Comput Assist Tomogr. 2004 Mar-Apr; 28(2):209-14. View in: Pubmed

    • Endovascular papillary angioendothelioma (Dabska tumor) of bone. Orthopedics. 2004 Mar; 27(3):327-8. View in: Pubmed

    • Multiple enhancing lesions detected on dynamic helical computed tomography-mammography. J Comput Assist Tomogr. 2003 Sep-Oct; 27(5):771-8. View in: Pubmed

    • Magnetic resonance imaging findings in gynecologic emergencies. J Comput Assist Tomogr. 2003 Jul-Aug; 27(4):564-70. View in: Pubmed

    • Primary retroperitoneal neoplasms: CT and MR imaging findings with anatomic and pathologic diagnostic clues. Radiographics. 2003 Jan-Feb; 23(1):45-57. View in: Pubmed

    • Journal of Women’s Imaging. MR Appearance of the Mature Cystic Teratoma of the Ovary with Malignant Transformation to Spindle Cell Carcinoma. 2003; (5):83-86. View in: Pubmed

    • Head and neck tuberculosis. Clinical Imagiology. 2003; (19):508-515. Review (in Japanese).. View in: Pubmed

    • Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003 Jan; 180(1):129-34. View in: Pubmed

    • MRI of early unruptured ectopic pregnancy: detection of gestational sac. J Comput Assist Tomogr. 2002 Jan-Feb; 26(1):134-7. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana Building Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana Building Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Discovery and Insights